A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798).
Knox
J J
JJ
Princess Margaret Hospital Phase II Consortium, and University Health Network, University of Toronto, Toronto, Ontario, Canada. jennifer.knox@uhn.on.ca
Chen
X E
XE
Feld
R
R
Nematollahi
M
M
Cheiken
R
R
Pond
G
G
Zwiebel
J A
JA
Gill
S
S
Moore
M
M
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D013873:Thionucleotides / Q000008:administration & dosage; D016896:Treatment Outcome
D019253:Proto-Oncogene Proteins c-bcl-2; D013873:Thionucleotides; D004317:Doxorubicin; C408162:oblimersen